Gunderson Dettmer announced today that Heidi Walas has joined the firm’s leading emerging companies practice, resident in the Silicon Valley office.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP has elected six new partners, effective January 1. The elevations span the U.S. and add to the firm’s corporate and securities, venture and growth equity fund, public offerings/public companies, executive compensation and tax practices.
Employers must file information returns with the Internal Revenue Service and provide employees with information statements related to incentive stock option exercises that occurred during calendar year 2020. Similarly, employers (typically relevant only for public companies) must file information returns with the IRS and provide employees with information statements related to initial transfers of stock acquired during 2020 under an employee stock purchase plan that complies with Internal Revenue Code Section 423.
Gunderson Dettmer represented client Cockroach Labs, an open-source database platform, in its $160 million Series E financing round led by Altimeter Capital Management.
Gunderson Dettmer represented client Gro Intelligence, an AI-powered insights company, in its $85 million Series B financing round co-led by Intel Africa and Africa Internet Ventures.
Gunderson Dettmer advised client Athlon Acquisition Corp. on its initial public offering of 24,000,000 shares at the price to the public of $10.00 per share.
Gunderson Dettmer represented client Genalyte, a leading diagnostics and analytics company, in its $50 million financing round led by Verily.
On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law.
Gunderson Dettmer represented client Affinivax, a clinical stage biopharmaceutical company, in its $226 million Series C financing co-led by Rock Springs Capital and Foresite Capital.
Gunderson Dettmer represented clients Altimeter, D1, Coatue and Dragoneer in the $525 million Series D financing of Lacework, a cloud security startup.
Gunderson Dettmer represented client Xencor, a clinical-stage biopharmaceutical company, in its collaboration agreement with MD Anderson to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
Gunderson Dettmer represented clients Altimeter and Dragoneer as they co-led the $520 million Series H financing of Roblox, a global online platform bringing people together through play.
Gunderson Dettmer represented client Coatue as it co-led the $300 million Series D financing of Hinge Health, a patient-centered Digital Clinic for back and joint pain.
Gunderson Dettmer represented Dragoneer in increasing its investment in PointClickCare, a cloud-based healthcare software for the long-term and post-acute care market.
Gunderson Dettmer represented client WeRide, a Chinese startup developing autonomous vehicles, in its $200 million Series B financing round led by Yutong Group.
Gunderson Dettmer client Barkbox, Inc., a leading global omni-channel brand for dogs, announced its definitive merger agreement with Northern Star Acquisition Corporation, a publicly-traded special purpose acquisition company (SPAC).
Gunderson Dettmer represented client GoCardless, an online-payment platform, in its $95 million Series F financing led by Bain Capital Ventures.
Gunderson Dettmer advised client ContextLogic Inc. dba Wish on its initial public offering of 46,000,000 shares of Class A common stock at a price to the public of $24.00 per share for a total of approximately $1.1 billion in aggregate gross proceeds.
Gunderson Dettmer represented Sofinnova as it led the $55 million Series A financing of Atsena Therapeutics, a clinical-stage gene therapy company.
Gunderson Dettmer represented client Overland Pharma in its joint venture with Allogene Therapeutics forming new company, Allogene Overland Biopharm, a separate venture that will develop, manufacture and commercialize allogeneic CAR T (AlloCAR T™) therapies for patients with cancer in greater China, Taiwan, South Korea and Singapore.
Gunderson Dettmer represented client Poynt, a payments processing startup, in its $320 million acquisition by GoDaddy.
Gunderson Dettmer’s Singapore office, opened in 2016 to meet the needs of emerging companies and venture capital investors across SE Asia, was ranked in Band 1 by Chambers and Partners in its 2021 Asia-Pacific guide for its Startups & Emerging Companies practice. Singapore managing partner Jonathan Pentzien was also recognized by Chambers in Band 1 as a leading individual for Startups & Emerging Companies. Chambers and Partners is the leading independent legal ranking publication globally and ranks Gunderson highly across all of its practice area
Gunderson Dettmer represented client Dubsmash, a lip-syncing video application, in its acquisition by Reddit.
Gunderson Dettmer represented client Overland Pharma in its joint venture with ADC Therapeutics forming new company, Overland ADCT BioPharma (CY) Limited, that will develop and commercialize four of ADC Therapeutics’ antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors in greater China and Singapore.
Gunderson Dettmer represented client Cityblock Health, a startup improving health care for low-income patients with complex medical needs, in its $160 million Series C financing led by General Catalyst.
With the passage of Senate Bill 826 at the end of September 2018, California became the first state in the U.S. to require public companies incorporated in California or other public companies with their principal executive offices in California (according their Annual Report on Form 10-K) to have specified numbers of women serving on their Boards of Directors. In addition, with the passage of Assembly Bill 979, these same public companies will be required to have at least two members of their Boards of Directors from an “underrepresented community.”
Gunderson Dettmer represented client PepGen, a therapeutics company targeting severe neuromuscular diseases, in its $45 million Series A financing led by RA Capital Management.
Gunderson Dettmer represented client Squire, a startup that sells software to barbershops, in its $60 million Series C financing led by Iconiq Capital. The raise is $45 million in equity capital and $15 million in debt financing.
Gunderson Dettmer represented client Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, in its research collaboration and license agreement with Janssen Biotech, Inc.
Gunderson Dettmer represented client Veran Medical Technologies, an interventional pulmonology device, in negotiating and entering into an acquisition agreement with Olympus.
- Page 1 of 18